212 related articles for article (PubMed ID: 37237269)
21. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4.
Huang DC; Adams JM; Cory S
EMBO J; 1998 Feb; 17(4):1029-39. PubMed ID: 9463381
[TBL] [Abstract][Full Text] [Related]
22. B cell lymphoma 2 (Bcl-2) residues essential for Bcl-2's apoptosis-inducing interaction with Nur77/Nor-1 orphan steroid receptors.
Banta KL; Wang X; Das P; Winoto A
J Biol Chem; 2018 Mar; 293(13):4724-4734. PubMed ID: 29414782
[TBL] [Abstract][Full Text] [Related]
23. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death.
Reed JC; Zha H; Aime-Sempe C; Takayama S; Wang HG
Adv Exp Med Biol; 1996; 406():99-112. PubMed ID: 8910675
[TBL] [Abstract][Full Text] [Related]
24. Clostridium difficile toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression, triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model.
Zhang Y; Li Y; Li H; Chen W; Liu W
Biomed Pharmacother; 2018 May; 101():391-398. PubMed ID: 29501042
[TBL] [Abstract][Full Text] [Related]
25. R5, a neutralizing antibody to Robo1, suppresses breast cancer growth and metastasis by inhibiting angiogenesis via down-regulating filamin A.
Li Q; Cao J; He Y; Liu X; Mao G; Wei B; Liao S; Zhang Q; Li J; Zheng L; Wang L; Qi C
Exp Cell Res; 2020 Feb; 387(1):111756. PubMed ID: 31811830
[TBL] [Abstract][Full Text] [Related]
26. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
27. Bcl-x(S) can form homodimers and heterodimers and its apoptotic activity requires localization of Bcl-x(S) to the mitochondria and its BH3 and loop domains.
Lindenboim L; Borner C; Stein R
Cell Death Differ; 2001 Sep; 8(9):933-42. PubMed ID: 11526448
[TBL] [Abstract][Full Text] [Related]
28. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo.
Zhang PC; Liu X; Li MM; Ma YY; Sun HT; Tian XY; Wang Y; Liu M; Fu LS; Wang YF; Chen HY; Liu Z
Biochem Pharmacol; 2020 Feb; 172():113771. PubMed ID: 31863779
[TBL] [Abstract][Full Text] [Related]
29. Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.
George J; Banik NL; Ray SK
J Cell Mol Med; 2009 Oct; 13(10):4205-18. PubMed ID: 19473291
[TBL] [Abstract][Full Text] [Related]
30. Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.
Park D; Anisuzzaman ASM; Magis AT; Chen G; Xie M; Zhang G; Behera M; Sica GL; Ramalingam SS; Owonikoko TK; Deng X
Theranostics; 2021; 11(17):8500-8516. PubMed ID: 34373755
[No Abstract] [Full Text] [Related]
31. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways.
Song Y; Dai F; Zhai D; Dong Y; Zhang J; Lu B; Luo J; Liu M; Yi Z
Angiogenesis; 2012 Sep; 15(3):421-32. PubMed ID: 22669534
[TBL] [Abstract][Full Text] [Related]
32. Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling.
Han B; Zhang H; Tian R; Liu H; Wang Z; Wang Z; Tian J; Cui Y; Ren S; Zuo X; Tian R; Niu R; Zhang F
Theranostics; 2022; 12(9):4127-4146. PubMed ID: 35673569
[No Abstract] [Full Text] [Related]
33. Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells.
Lu Q; Lv M; Xu E; Shao F; Feng Y; Yang J; Shi L
Oncol Rep; 2015 Mar; 33(3):1358-64. PubMed ID: 25592110
[TBL] [Abstract][Full Text] [Related]
34. Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative.
Yi EY; Jeong EJ; Song HS; Lee MS; Kang DW; Joo JH; Kwon HS; Lee SH; Park SK; Chung SG; Cho EH; Kim YJ
Int J Oncol; 2004 Aug; 25(2):365-72. PubMed ID: 15254733
[TBL] [Abstract][Full Text] [Related]
35. Insights from diversified anti-angiogenic models: Role of β-interferon inducer DEAE-Dextran.
Bakrania AK; Variya BC; Patel SS
Pharmacol Rep; 2018 Jun; 70(3):549-557. PubMed ID: 29677525
[TBL] [Abstract][Full Text] [Related]
36. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl.
Monaco G; Decrock E; Akl H; Ponsaerts R; Vervliet T; Luyten T; De Maeyer M; Missiaen L; Distelhorst CW; De Smedt H; Parys JB; Leybaert L; Bultynck G
Cell Death Differ; 2012 Feb; 19(2):295-309. PubMed ID: 21818117
[TBL] [Abstract][Full Text] [Related]
37. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
Han B; Park D; Li R; Xie M; Owonikoko TK; Zhang G; Sica GL; Ding C; Zhou J; Magis AT; Chen ZG; Shin DM; Ramalingam SS; Khuri FR; Curran WJ; Deng X
Cancer Cell; 2015 Jun; 27(6):852-63. PubMed ID: 26004684
[TBL] [Abstract][Full Text] [Related]
38. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.
Ma Q; Chen W; Chen W
Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645
[TBL] [Abstract][Full Text] [Related]
40. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
Raghav PK; Verma YK; Gangenahalli GU
Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
